Management Team

Jon Northrup, MBA, CLP

Chief Executive Officer

Mr. Northrup brings broad experience to BetaCat, having worked at Eli Lilly and Company as an executive in Finance, Marketing, Sales, Corporate Business Development and Corporate Strategy; in management consulting with Asian companies, and in founding the venturing group with Jubilant Life Sciences. Mr. Northrup is a Certified Licensing Professional in the Licensing Executive Society, received his MBA from the Wharton School of the University of Pennsylvania in Finance, and received his BA in Economics from Northwestern University.

Casey Cunningham, MD

Chief Medical Officer

Casey received his medical degree from the University of Texas Southwestern Medical School with a residency in Internal Medicine at the Medical College of Wisconsin. His roles include joinging Santé Ventures shortly after its founding as CSO.  He has served in operating roles in Terapio, and Molecular Templates and is currently on, the Boards of Terapio Corp., Molecular Templates, Lyric Pharmaceuticals, AbVitro and Mirna Therapeutics.

Steve Horrigan, PHD

Chief Scientific Officer

Dr. Horrigan brings 20+ Years of experience in  Cancer Drug Developmen.  His career has included the Role of Chief Scientific  Avalon Pharma – CSO; Molecular Geneticist; Noble Life Sciences – CSO Georgetown – He is also an Associate Professor.

              Scott Jordan                  Chief Financial Officer

Mr. Jordan brings 25+ Years of Life Sciences Experience in Banking/Finance and Senior-level Management; which includes previous experience as  HealthiosXchange - Co-Founder; Healthios Capital Markets - VP; S. Jordan Associates - CEO; NeoPharm - Director of Business Development; Akorn Opthalmics - Regional Manager; Abbott Labs - National Accounts.

       Neil Sankar, MD,MPH              Snr. Medical Director & Monitor

Dr. Sankar received his MD degree from Bangalore University and internal medicine residency from Univ. of West indies, Kingston, Jamaica. He did his clinical research training and tumor biology from NCI Bethesda Maryland and since has held senior level positions in clinical development with leading Biotech/Pharma.  He has also provided global clinical development and regulatory strategies for therapeutic drugs.  Dr. Sankar was instrumental in filling the NDA for the antibody-drug conjugate in Metastic Breast Cancer and the Bruton tyrosine Kinase inhibitor in Mantle cell Lymphoma

Jeff Larson, PHD, DABT
VP of Non Clinical Development

Dr. Larson brings a 24+ year career that included the role VP of BioAlliance, where he provided a wide array of consulting services and development for  like companies. He was also an independent consultant providing contracting services, toxicology consulting, and litigation expert testimony. He has  led preclinincal development, including toxicology and pharmacokinetics, across a number of companies including; NexBio (Asun), Tanox, Sierra Biomedical (a Charles River Laboratories company), Aronex Pharmaceuticals, and Allergan.

           Uma Bhatt, CPA            Chief Accounting Officer, Controller 

Mrs. Bhatt comes with extensive hands on and executive management experience as a CFO, COO, Corporate Controller, Financial Reporting Manager/Director of Finance, Senior Finance Analyst with international experience of Controllership, Business Development, Internal Auditing & Tax.  

  Rose Hernandez   Clinical Operations Director

17+ years of global cllinical research exerience within the parmaceutical and medical device industry.  Her previous potsitions include Brain Sentinel where she was the Sr. Director of Medical Affairs & Regulatory Complaince; and before that she was the Director of Clinical Affairs at CeloNova.

    Srinivas Kasibhatla, PHD            VP Discovery Chemistry

Prior to joining BetaCat Dr. Kasibhatla served as the Vice President of Chemistry at Xetrios Therapeutics, he was also the Head of Discovery Chemistry at BMS research center Bangalore. Dr. Kasibhatla has led discovery chemistry teams in multiple therapeutic areas advancing compounds into preclinical and clinical development. Dr. Kasibhatla received his MS and PhD from the University of Hyderabad and Postdoctoral Fellowship at Harvard University.